NEW YORK & GREENVILLE, S.C.--(BUSINESS WIRE)--Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ solutions as prescription medical treatments, today announced a partnership with youturn, the leader in evidence-based and therapist-led video content about substance use disorder, providing Clickotine®, a clinically validated, fully digital smoking cessation program, to youturn’s enterprise customers spanning nearly 5,000 members around the world.

Clickotine is an all in one, comprehensive digital therapeutic for smoking cessation that can be downloaded on a smartphone. The program provides an individualized plan that is fully integrated with 8 weeks of nicotine replacement therapy including gum, a patch or lozenge. By partnering with Click, youturn, a cost-saving online solution that employers can enroll in to provide resources and support for those who may be struggling with substance use disorder, will grant all members access to Clickotine’s digital regimen.

The partnership aims to provide better tools and resources for members trying to achieve their smoking quit goals in combination with youturn’s vast substance use disorder resource library. A study published in The Journal of Clinical Psychiatry concludes that incorporating smoking cessation and prevention efforts into substance use disorder treatment may improve long-term outcomes for adult smokers with substance use disorders, supporting a natural alliance between Click and youturn.

“Our partnership with youturn underscores the widespread need and power of innovative healthcare solutions for the treatment of behavioral and physical health problems like smoking,” said David Benshoof Klein, chief executive officer at Click Therapeutics. “Clickotine has a verified history of guiding patients through the smoking cessation process in addition to curbing overall healthcare costs. We are thrilled to collaborate with youturn as we align on our combined mission of leveraging digital platforms to help patients with neurobehavioral conditions live longer, happier and healthier lives.”

“Partnering with a leading digital healthcare company like Click Therapeutics is an exciting step in our organization’s quest to help patients and families affected by smoking and other mood-altering behaviors that are often stigmatized,” said Shay Houser, co-founder and chief executive officer at youturn. “Our goal is to lower the significant costs and impacts of addiction and substance use disorder on our healthcare system. Clickotine, as well as Click’s overall dedication to developing software as prescription medical treatments for a wide array of indications, fulfills our mission of providing evidence-based, technological resources for patients and families in need. We look forward to witnessing the positive impact of Clickotine on youturn members.”

Click Therapeutics, Inc. develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. We are expanding the possibilities of medicine with Digital Therapeutics™ that combine clinical science with the power of software to create a new way to treat disease.  

Operating at the intersection of biology and technology, we use a proprietary platform-based approach to therapeutic development that leverages patient-centric design principles and innovative AI-based technologies to deliver a unique combination of engagement and clinical outcomes, consistently. Digital therapeutics on Click’s platform are regulated, clinically validated prescription mobile applications that can address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, immunology, and cardiometabolic diseases. 

Click Therapeutics, in collaboration with Otsuka, developed the first prescription digital therapeutic authorized by the FDA for the adjunctive treatment of major depressive disorder symptoms, Rejoyn™. In October 2024, in response to FDA guidance on prescription drug use-related software (PDURS), we launched Click SE™ to extend our digital therapeutics platform and expertise to the development of software-enhanced drug™ therapies that combine software with pharmacotherapy to offer added clinically meaningful benefit to patients.

Our commitment to advancing digital medicine means we continually improve our platform technologies, ensuring we stay at the forefront of cognitive, behavioral, and neuromodulatory therapeutic innovation, to achieve the best possible outcomes for patients. Our diverse team of innovators—spanning clinicians, researchers, technologists, designers and more—works together to create cutting-edge digital therapeutics, united in the mission to transform patient care. For more information, visit www.clicktherapeutics.com and connect with us on LinkedIn.

youturn maintains the world's largest library of proprietary, evidence-based and therapist-led video content about substance misuse. Developed after engaging with 40,000 individuals through nationally-recognized, non-profit partner, FAVOR Greenville, youturn provides evidenced-based training content to enterprises. These training protocols reduce risk related to drugs and alcohol while also increasing employee resilience and productivity. It also helps to contain health plan costs. For more information: https://youturn.net/.